CCEL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
7.8M
+1.2%
7.7M
-2.0%
7.8M
+0.2%
7.8M
-1.3%
7.9M
Cost of Revenue
1.7M
+1.2%
1.7M
-4.5%
1.7M
-3.7%
1.8M
-3.0%
1.9M
Gross Profit
6.1M
+1.2%
6.0M
-1.3%
6.1M
+1.4%
6.0M
-0.8%
6.1M
Operating Expenses
4.9M
-6.8%
5.3M
-47.8%
10.1M
+144.4%
4.1M
-10.0%
4.6M
R&D
99.8K
+51.7%
65.8K
-22.4%
84.8K
+37.6%
61.6K
-53.2%
131.7K
SG&A
4.6M
-7.9%
5.0M
-8.0%
5.4M
+40.6%
3.9M
-9.0%
4.3M
Operating Income
1.2M
+56.5%
765.1K
+119.3%
-3966787
-308.7%
1.9M
+27.3%
1.5M
EBITDA
1.4M
+42.8%
1.0M
+58.9%
635.1K
-69.7%
2.1M
+20.3%
1.7M
Net Income
554.6K
+1077.3%
47.1K
+101.2%
-3817433
-609.4%
749.4K
+110.6%
355.8K
EPS (Basic)
$0.07
+600.0%
$0.01
+102.1%
$-0.47
-622.2%
$0.09
+125.0%
$0.04
EPS (Diluted)
$0.07
+600.0%
$0.01
+102.1%
$-0.48
-633.3%
$0.09
+125.0%
$0.04
Shares (Diluted)
8.1M
-0.0%
8.1M
+2.3%
7.9M
-2.5%
8.1M
-0.6%
8.1M
Cryo-Cell International (CCEL) โ€” Financials